Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001764013-25-000087
Filing Date
2025-04-30
Accepted
2025-04-30 16:06:19
Documents
16
Effectiveness Date
2025-04-30

Document Format Files

Seq Description Document Type Size
1 S-8 imvt-20250430xsx8.htm S-8 80695
2 EX-FILING FEES exfilingfees4-30.htm   iXBRL EX-FILING FEES 12713
3 EX-5.1 exhibit5120250430.htm EX-5.1 13176
4 EX-23.1 exhibit23120250430.htm EX-23.1 2276
5 GRAPHIC picture1.jpg GRAPHIC 2972
  Complete submission text file 0001764013-25-000087.txt   240393

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT exfilingfees4-30_htm.xml XML 4725
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: S-8 | Act: 33 | File No.: 333-286848 | Film No.: 25894984
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)